Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""SALVAGE therapy"" wg kryterium: Temat


Tytuł :
Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers.
Autorzy :
Chin JL; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Lavi A; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Metcalfe MJ; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Siddiqui K; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Dewar M; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Petros FG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Li R; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nogueras González GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nair SM; Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada.
Ward JF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pisters L; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Sep; Vol. 206 (3), pp. 646-654. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms :
Cryosurgery/*adverse effects
Neoadjuvant Therapy/*methods
Neoplasm Recurrence, Local/*therapy
Postoperative Complications/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*therapy
Salvage Therapy/*adverse effects
Aged ; Androgen Antagonists/pharmacology ; Androgen Antagonists/therapeutic use ; Chemotherapy, Adjuvant/statistics & numerical data ; Follow-Up Studies ; Humans ; Kallikreins/blood ; Male ; Neoadjuvant Therapy/statistics & numerical data ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/mortality ; Postoperative Complications/etiology ; Prospective Studies ; Prostate/pathology ; Prostate/radiation effects ; Prostate/surgery ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/mortality ; Radiation Tolerance ; Radiotherapy, Adjuvant/statistics & numerical data ; Retrospective Studies ; Salvage Therapy/methods ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Twenty-year experience with salvage total laryngectomy: lessons learned.
Autorzy :
Tsetsos N; Department of Otorhinolaryngology - Head and Neck Surgery, 'G. Papanikolaou' General Hospital, Thessaloniki, Greece.
Poutoglidis A; Department of Otorhinolaryngology - Head and Neck Surgery, 'G. Papanikolaou' General Hospital, Thessaloniki, Greece.
Vlachtsis K; Department of Otorhinolaryngology - Head and Neck Surgery, 'G. Papanikolaou' General Hospital, Thessaloniki, Greece.
Stavrakas M; Department of Otorhinolaryngology - Head and Neck Surgery, Derriford Hospital University Hospitals Plymouth NHS Trust, Plymouth, UK.
Nikolaou A; Department of Otorhinolaryngology - Head and Neck Surgery, 'G. Papanikolaou' General Hospital, Thessaloniki, Greece.
Fyrmpas G; Department of Otorhinolaryngology - Head and Neck Surgery, 'G. Papanikolaou' General Hospital, Thessaloniki, Greece.
Pokaż więcej
Źródło :
The Journal of laryngology and otology [J Laryngol Otol] 2021 Aug; Vol. 135 (8), pp. 729-736. Date of Electronic Publication: 2021 Jul 05.
Typ publikacji :
Journal Article
MeSH Terms :
Laryngectomy*/adverse effects
Laryngectomy*/mortality
Laryngectomy*/statistics & numerical data
Salvage Therapy*/adverse effects
Salvage Therapy*/mortality
Salvage Therapy*/statistics & numerical data
Aged ; Female ; Humans ; Kaplan-Meier Estimate ; Laryngeal Neoplasms/surgery ; Male ; Middle Aged ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł :
Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
Autorzy :
Khedime S; Service dúrologie, chirurgie de la transplantation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Gelet A; LabTAU, INSERM, Université Lyon 1, Lyon, France.
Rouvière O; LabTAU, INSERM, Université Lyon 1, Lyon, France.; Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France.; Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Lafon C; Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France.
Badet L; Service dúrologie, chirurgie de la transplantation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.; Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France.
Crouzet S; Service dúrologie, chirurgie de la transplantation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.; LabTAU, INSERM, Université Lyon 1, Lyon, France.; Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France.
Hostiou T; Service dúrologie, chirurgie de la transplantation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.; LabTAU, INSERM, Université Lyon 1, Lyon, France.; Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Aug; Vol. 206 (2), pp. 325-337. Date of Electronic Publication: 2021 Apr 09.
Typ publikacji :
Journal Article
MeSH Terms :
Salvage Therapy*
Ultrasound, High-Intensity Focused, Transrectal*
Neoplasm Recurrence, Local/*therapy
Prostatic Neoplasms/*therapy
Follow-Up Studies ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Prostatectomy ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Radiotherapy, Adjuvant ; Retrospective Studies ; Urinary Incontinence/etiology
Czasopismo naukowe
Tytuł :
Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Autorzy :
Fuji S; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 5418567, Japan. .
Kida S; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 5418567, Japan.
Nakata K; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Morishima T; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Miyashiro I; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Ishikawa J; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 5418567, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Sep; Vol. 100 (9), pp. 2253-2260. Date of Electronic Publication: 2020 Nov 09.
Typ publikacji :
Journal Article
MeSH Terms :
Salvage Therapy*
Antineoplastic Agents, Immunological/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*therapy
Neoplasm Recurrence, Local/*therapy
Rituximab/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Prednisone/therapeutic use ; Survival Analysis ; Transplantation, Autologous ; Vincristine/therapeutic use ; Young Adult
SCR Protocol :
CHOP protocol
Czasopismo naukowe
Tytuł :
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Autorzy :
Lynch RC; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cassaday RD; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Smith SD; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fromm JR; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Cowan AJ; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Warren EH; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shadman MS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shustov A; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Till BG; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ujjani CS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Libby EN 3rd; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Philip M; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Coye H; Seattle Cancer Care Alliance, Seattle, WA, USA.
Martino CN; Seattle Cancer Care Alliance, Seattle, WA, USA.
Bhark SL; Seattle Cancer Care Alliance, Seattle, WA, USA.
Morris K; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Rasmussen H; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Behnia S; Department of Radiology, University of Washington, Seattle, WA, USA.
Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gopal AK; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e562-e571.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Resistance, Neoplasm/*drug effects
Hodgkin Disease/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adult ; Brentuximab Vedotin/administration & dosage ; Carboplatin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Hodgkin Disease/pathology ; Humans ; Ifosfamide/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Therapeutic plasma exchange (TPE) as a plausible rescue therapy in severe vaccine-induced immune thrombotic thrombocytopenia.
Autorzy :
Rock G; Canadian Apheresis Group, Ottawa, Canada. Electronic address: .
Weber V; Department for Biomedical Research, Center for Biomedical Technology, Danube University, Krems, Austria. Electronic address: .
Stegmayr B; Department of Public Health and Clinical Medicine, Faculty of Medicine, Umea University, Umea, Sweden. Electronic address: .
Pokaż więcej
Źródło :
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2021 Aug; Vol. 60 (4), pp. 103174. Date of Electronic Publication: 2021 May 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Plasma Exchange*/adverse effects
Plasma Exchange*/methods
Salvage Therapy*
COVID-19 Vaccines/*adverse effects
Platelet Factor 4/*immunology
Purpura, Thrombotic Thrombocytopenic/*therapy
Albumins ; Antibody Specificity ; Anticoagulants ; Autoantibodies/immunology ; COVID-19 Vaccines/pharmacology ; Citrates ; Contraindications, Procedure ; Cytokines/blood ; Extracellular Vesicles ; Humans ; Immunoglobulin G/immunology ; Immunosuppression ; Inflammation ; Platelet Activation ; Platelet Transfusion/adverse effects ; Purpura, Thrombotic Thrombocytopenic/etiology ; Purpura, Thrombotic Thrombocytopenic/immunology ; Registries ; Thrombocytopenia/etiology ; Thrombosis/etiology
SCR Disease Name :
Thrombotic thrombocytopenic purpura, acquired
Czasopismo naukowe
Tytuł :
Salvage interstitial laser thermal therapy under MRI guidance (MRgFLA) for high-intensity focal ultrasound (HIFU) recurrences: feasibility study.
Autorzy :
Magee D; Division of Urology, Department of Surgery, University Health Network, University of Toronto, Canada.
Perlis N; Division of Urology, Department of Surgery, University Health Network, University of Toronto, Canada.
Corr K; Division of Urology, Department of Surgery, University Health Network, University of Toronto, Canada.
Chan R; Joint Department of Medical Imaging, University Health Network, University of Toronto, Canada.
Gertner M; Joint Department of Medical Imaging, University Health Network, University of Toronto, Canada.
Zisman A; Techna Institute, University Health Network, University of Toronto, Canada.
Jokhu S; Division of Urology, Department of Surgery, University Health Network, University of Toronto, Canada.
Ghai S; Joint Department of Medical Imaging, University Health Network, University of Toronto, Canada. Electronic address: .
Pokaż więcej
Źródło :
Clinical imaging [Clin Imaging] 2021 Aug; Vol. 76, pp. 217-221. Date of Electronic Publication: 2021 Apr 28.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/therapy
Salvage Therapy*
Feasibility Studies ; Humans ; Lasers ; Magnetic Resonance Imaging ; Male ; Neoplasm Recurrence, Local/diagnostic imaging ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Autorzy :
Liebers N; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Duell J; Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany.
Fitzgerald D; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; European Molecular Biology Laboratory, Heidelberg, Germany.
Kerkhoff A; Department of Medicine A, University Hospital Münster, Münster, Germany.
Noerenberg D; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
Kaebisch E; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
Acker F; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany.
Fuhrmann S; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
Leng C; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany.
Welslau M; MVZ am Klinikum Aschaffenburg, Onkologie und Hämatologie, Aschaffenburg, Germany.
Chemnitz J; Gemeinschaftsklinikum Mittelrhein GmbH, Koblenz, Germany.
Middeke JM; University Hospital Dresden, Dresden, Germany.
Weber T; Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany.
Holtick U; Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany.
Trappe R; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.
Pfannes R; Department of Medicine I, Städtisches Klinikum Dessau, Dessau, Germany.
Liersch R; Praxis Medical Center, Gemeinschaftspraxis für Hämatologie und Onkologie Münster, Münster, Germany.
Spoer C; MVZ am EVK Düsseldorf, Internistische Onkologie und Hämatologie, Düsseldorf, Germany.
Fuxius S; Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany.
Gebauer N; Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Germany.
Caillé L; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Geer T; Diakonie Klinikum Schwäbisch-Hall, Innere Medizin III, Schwäbisch Hall, Germany.
Koenecke C; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Keller U; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany.
Claus R; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
Mougiakakos D; Department of Internal Medicine 5, Hematology and Clinical Oncology, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Erlangen, Germany.
Mayer S; Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany.
Huettmann A; Department of Hematology, University Hospital of Essen, Essen, Germany.
Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Trummer A; Department of Hematology and Oncology, Klinikum Braunschweig, Braunschweig, Germany.
Wulf G; Clinic for Hematology and Medical Oncology, University Medicine Göttingen, Germany; and.
Brunnberg U; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany.
Bullinger L; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
Hess G; Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, Mainz, Germany.
Mueller-Tidow C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Glass B; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
Lenz G; Department of Medicine A, University Hospital Münster, Münster, Germany.
Dreger P; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Dietrich S; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory, Heidelberg, Germany.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Jul 13; Vol. 5 (13), pp. 2707-2716.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunoconjugates*
Salvage Therapy*
Antibodies, Monoclonal ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Long-term outcomes of salvage endoscopic submucosal dissection for local failure after chemoradiotherapy for esophageal squamous cell carcinoma.
Autorzy :
Kimura H; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshida M; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Yabuuchi Y; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kakushima N; Department of Gastroenterology & Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yamamoto Y; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kawata N; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Takizawa K; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kishida Y; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Imai K; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Ito S; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Hotta K; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Ishiwatari H; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Matsubayashi H; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Ono H; Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Jul 01; Vol. 51 (7), pp. 1036-1043.
Typ publikacji :
Journal Article
MeSH Terms :
Chemoradiotherapy*
Endoscopic Mucosal Resection*
Salvage Therapy*
Esophageal Neoplasms/*therapy
Esophageal Squamous Cell Carcinoma/*therapy
Aged ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Autorzy :
Liu M; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Deng H; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Mu J; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Li Q; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Pu Y; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Jiang Y; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Deng Q; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Qian Z; Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jul; Vol. 112 (7), pp. 2642-2651. Date of Electronic Publication: 2021 May 10.
Typ publikacji :
Journal Article
MeSH Terms :
Receptors, Chimeric Antigen*/genetics
Salvage Therapy*
Adenine/*analogs & derivatives
Immunotherapy, Adoptive/*methods
Lymphoma, Follicular/*therapy
Lymphoma, Mantle-Cell/*therapy
Piperidines/*therapeutic use
Adenine/therapeutic use ; Adult ; Aged ; Combined Modality Therapy/methods ; Disease Progression ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunotherapy, Adoptive/adverse effects ; Interleukin-6/blood ; Interleukin-8/blood ; Lymphoma, B-Cell/blood ; Lymphoma, B-Cell/therapy ; Lymphoma, Follicular/blood ; Lymphoma, Large B-Cell, Diffuse/blood ; Lymphoma, Large B-Cell, Diffuse/therapy ; Lymphoma, Mantle-Cell/blood ; Male ; Middle Aged ; Receptors, Interleukin-2/blood ; Remission Induction/methods ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).
Autorzy :
Touzeau C; Service d'hématologie clinique, Hôtel Dieu, Nantes, France. .; CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. .; Site de Recherche Intégrée sur le Cancer (SIRIC) « ILIAD », Nantes, France. .
Quignot N; Certara Evidence & Access, Paris, France.
Meng J; Certara Evidence & Access, Lorrach, Germany.
Jiang H; Certara Evidence & Access, Paris, France.
Khachatryan A; Certara Evidence & Access, London, UK.
Singh M; Amgen Ltd, London, UK.
Taieb V; Amgen Ltd, London, UK.
Chauny JV; Amgen SAS, Boulogne-Billancourt, France.
Désaméricq G; Amgen SAS, Boulogne-Billancourt, France.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1825-1836. Date of Electronic Publication: 2021 Apr 21.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*mortality
Aged ; Combined Modality Therapy ; Comorbidity ; Databases, Factual ; Datasets as Topic ; Drug Resistance, Neoplasm ; France/epidemiology ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; National Health Programs/statistics & numerical data ; Recurrence ; Retrospective Studies ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
Autorzy :
Swoboda R; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Giebel S; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Knopińska-Posłuszny W; Department of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals, Gdynia, Poland.
Chmielowska E; Oncologic Hospital, Tomaszów Mazowiecki, Poland.; Department of Oncology, Oncology Centre, Bydgoszcz, Poland.
Drozd-Sokołowska J; Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Paszkiewicz-Kozik E; Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw branch, Warsaw, Poland.
Kulikowski W; Department of Hematology, Independent Public Health Care Ministry of the Interior of Warmia and Mazury Oncology Center, Olsztyn, Poland.
Taszner M; Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Mendrek W; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Najda J; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Czerw T; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Olszewska-Szopa M; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland.
Czyż A; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland.
Giza A; Department of Hematology, Jagiellonian University, Krakow, Poland.
Spychałowicz W; Internal Medicine and Oncology Clinic, Silesian Medical University, Katowice, Poland.
Subocz E; Department of Hematology, Military Institute of Medicine, Warsaw, Poland.
Szwedyk P; Department of Hematology, Ludwik Rydygier Hospital, Krakow, Poland.
Krzywon A; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Wilk A; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Zaucha JM; Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1755-1767. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hodgkin Disease/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/adverse effects ; Combined Modality Therapy ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Drug Evaluation ; Female ; Hematologic Diseases/chemically induced ; Hematopoietic Stem Cell Transplantation ; Hodgkin Disease/radiotherapy ; Hodgkin Disease/therapy ; Humans ; Infections/etiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Progression-Free Survival ; Radiotherapy, Adjuvant ; Recurrence ; Retrospective Studies ; Transplantation, Autologous ; Young Adult
Czasopismo naukowe
Tytuł :
Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.
Autorzy :
Cao F; Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 1 Banshan Dong Lu, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Zheng J; Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 1 Banshan Dong Lu, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Luo J; Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 1 Banshan Dong Lu, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Zhang Z; Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 1 Banshan Dong Lu, Gongshu District, Hangzhou, 310022, Zhejiang, China.
Shao G; Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 1 Banshan Dong Lu, Gongshu District, Hangzhou, 310022, Zhejiang, China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Oct; Vol. 147 (10), pp. 2993-3002. Date of Electronic Publication: 2021 Jul 24.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Delivery Systems*
Salvage Therapy*
Chemoembolization, Therapeutic/*mortality
Colorectal Neoplasms/*therapy
Liver Neoplasms/*therapy
Phenylurea Compounds/*therapeutic use
Pyridines/*therapeutic use
Colorectal Neoplasms/pathology ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms/secondary ; Male ; Microspheres ; Middle Aged ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Salvage of Malfunctioning Peritoneal Dialysis Catheters: An Algorithm for Recanalization and Repositioning.
Autorzy :
Li P; University of Alberta Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Choo D; Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.
Deved V; Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Shah N; Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Shurraw S; Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Zuidema S; University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.
Samji R; Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada. Electronic address: .
Pokaż więcej
Źródło :
Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2021 Jun; Vol. 32 (6), pp. 902-906. Date of Electronic Publication: 2021 Mar 23.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Algorithms*
Catheters, Indwelling*
Decision Support Techniques*
Radiography, Interventional*/adverse effects
Salvage Therapy*/adverse effects
Catheterization/*instrumentation
Peritoneal Dialysis/*instrumentation
Adolescent ; Adult ; Aged ; Catheterization/adverse effects ; Equipment Failure ; Female ; Humans ; Male ; Middle Aged ; Peritoneal Dialysis/adverse effects ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Autorzy :
Liu S; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Deng B; Cytology Laboratory, Beijing Boren Hospital, Beijing, China.
Yin Z; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Lin Y; Department of Hematology, Beijing Boren Hospital, Beijing, China.
An L; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Liu D; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Pan J; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Yu X; Medical Laboratory, Beijing Boren Hospital, Beijing, China.
Chen B; Medical Laboratory, Beijing Boren Hospital, Beijing, China.
Wu T; Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, China.
Chang AH; Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Tong C; Department of Hematology, Beijing Boren Hospital, Beijing, China.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Jun 01; Vol. 96 (6), pp. 671-679. Date of Electronic Publication: 2021 Mar 29.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antigens, CD19/*immunology
Antigens, Neoplasm/*immunology
Immunotherapy, Adoptive/*methods
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Sialic Acid Binding Ig-like Lectin 2/*immunology
4-1BB Ligand/genetics ; Adolescent ; Adult ; Allografts ; CD3 Complex/genetics ; Child ; Child, Preschool ; Combined Modality Therapy ; Cord Blood Stem Cell Transplantation ; Female ; Follow-Up Studies ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation ; Humans ; Infant ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Progression-Free Survival ; Recurrence ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Autorzy :
Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece. .
Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Moreau P; University Hospital Hôtel-Dieu, Nantes, France.
Anderson LD Jr; The University of Texas Southwestern Medical Center, Dallas, TX, USA.
White D; Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
San-Miguel J; Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
Sonneveld P; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Engelhardt M; Faculty of Freiburg, Universitätsklinikum Freiburg, Freiburg, Germany.
Jenner M; University Hospital Southampton, Southampton, UK.
Corso A; Division of Hematology, Hospital Legnano, Milan, Italy.
Dürig J; University Medicine Essen, Essen, Germany.
Pavic M; Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hôpital Fleurimont, Sherbrooke, QC, Canada.
Salomo M; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Casal E; Bristol Myers Squibb, Summit, NJ, USA.
Srinivasan S; Bristol Myers Squibb, Summit, NJ, USA.
Yu X; Bristol Myers Squibb, Summit, NJ, USA.
Nguyen TV; Bristol Myers Squibb, Summit, NJ, USA.
Biyukov T; Celgene International Sàrl, Bristol Myers Squibb Company, Boudry, Switzerland.
Peluso T; Celgene International Sàrl, Bristol Myers Squibb Company, Boudry, Switzerland.
Richardson P; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jun; Vol. 35 (6), pp. 1722-1731. Date of Electronic Publication: 2020 Sep 07.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Resistance, Neoplasm/*drug effects
Multiple Myeloma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives
Czasopismo naukowe
Tytuł :
Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
Autorzy :
Wang S; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wang X; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Ye C; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Cheng H; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shi M; Cancer Institute, Xuzhou Medical University, Xuzhou, China.
Chen W; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qi K; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wang G; Cancer Institute, Xuzhou Medical University, Xuzhou, China.
Wu Q; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, China.
Zeng L; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, China.
Li Z; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jing G; iCARTAB biomedical co. LTD, Suzhou, China.
Zheng J; Cancer Institute, Xuzhou Medical University, Xuzhou, China.; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xu K; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.; Jiangsu Bone Marrow Stem Cell Institute, Xuzhou, China.
Cao J; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E162-E165. Date of Electronic Publication: 2021 Feb 21.
Typ publikacji :
Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*
Salvage Therapy*
Antigens, CD19/*immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Animals ; Antibodies, Monoclonal, Humanized/immunology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Kaplan-Meier Estimate ; Male ; Mice ; Pilot Projects ; Remission Induction ; Single-Chain Antibodies/immunology ; Treatment Outcome
Raport
Tytuł :
A Systematic Review of Primary, Adjuvant, and Salvage Radiation Therapy for Cutaneous Squamous Cell Carcinoma.
Autorzy :
Krausz AE; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Ji-Xu A; Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Smile T; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.
Koyfman S; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.
Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Ruiz ES; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2021 May 01; Vol. 47 (5), pp. 587-592.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Radiotherapy, Adjuvant*
Salvage Therapy*
Carcinoma, Squamous Cell/*radiotherapy
Skin Neoplasms/*radiotherapy
Carcinoma, Squamous Cell/pathology ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Skin Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Editorial: Salvage therapy in uro-oncology.
Autorzy :
Heidenreich A; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.; Department of Urology, Medical University Vienna, Vienna, Austria.
Karnes RJ; Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
Current opinion in urology [Curr Opin Urol] 2021 May 01; Vol. 31 (3), pp. 177.
Typ publikacji :
Editorial
MeSH Terms :
Salvage Therapy*
Urology*
Humans ; Medical Oncology
Opinia redakcyjna
Tytuł :
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Autorzy :
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. .
Ishikawa T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Min CK; Seoul St. Mary's Hospital, Seoul, South Korea.
Kim K; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yeh SP; China Medical University Hospital, Taichung, Taiwan.
Usmani SZ; Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Mateos MV; University Hospital of Salamanca/IBSAL, Salamanca, Spain.
Nahi H; Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
Heuck C; Janssen Research & Development, LLC, Spring House, PA, USA.
Qin X; Janssen Research & Development, LLC, Raritan, NJ, USA.
Parasrampuria DA; Janssen Research & Development, LLC, Spring House, PA, USA.
Gries KS; Janssen Research & Development, LLC, Spring House, PA, USA.
Qi M; Janssen Research & Development, LLC, Spring House, PA, USA.
Bahlis N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
Ito S; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 1065-1077. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Salvage Therapy*
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Asian Continental Ancestry Group/*statistics & numerical data
Multiple Myeloma/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacokinetics ; Asian Continental Ancestry Group/psychology ; Body Weight ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Injections, Subcutaneous ; Japan/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/ethnology ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Neutropenia/chemically induced ; Patient Satisfaction ; Progression-Free Survival ; Republic of Korea/epidemiology ; Taiwan/epidemiology ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies